Association of soy food with cardiovascular outcomes and all-cause mortality in a Chinese population: a nationwide prospective cohort study

作者全名："Xue, Ting; Wen, Junping; Wan, Qin; Qin, Guijun; Yan, Li; Wang, Guixia; Qin, Yingfen; Luo, Zuojie; Tang, Xulei; Huo, Yanan; Hu, Ruying; Ye, Zhen; Shi, Lixin; Gao, Zhengnan; Su, Qing; Mu, Yiming; Zhao, Jiajun; Chen, Lulu; Zeng, Tianshu; Yu, Xuefeng; Li, Qiang; Shen, Feixia; Chen, Li; Zhang, Yinfei; Wang, Youmin; Deng, Huacong; Liu, Chao; Wu, Shengli; Yang, Tao; Li, Mian; Xu, Yu; Xu, Min; Wang, Tiange; Zhao, Zhiyun; Lu, Jieli; Bi, Yufang; Wang, Weiqing; Chen, Gang; Ning, Guang"

作者地址："[Xue, Ting] Fujian Med Univ, Shengli Clin Med Coll, South Branch, Ctr Hlth Management,Fujian Prov Hosp, Fuzhou, Peoples R China; [Wen, Junping; Chen, Gang] Fujian Med Univ, Shengli Clin Med Coll, Fujian Prov Hosp, Dept Endocrinol, Fuzhou, Peoples R China; [Wan, Qin] Luzhou Med Coll, Affiliated Hosp, Luzhou, Peoples R China; [Qin, Guijun] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Yan, Li] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China; [Wang, Guixia] First Hosp Jilin Univ, Changchun, Peoples R China; [Qin, Yingfen; Luo, Zuojie] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China; [Tang, Xulei] Lanzhou Univ, Hosp 1, Lanzhou, Peoples R China; [Huo, Yanan] Nanchang Univ, Jiangxi Prov Peoples Hosp, Nanchang, Jiangxi, Peoples R China; [Hu, Ruying] Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou, Peoples R China; [Ye, Zhen] Guiyang Med Coll, Affiliated Hosp, Guiyang, Peoples R China; [Shi, Lixin] Dalian Municipal Cent Hosp, Dalian, Peoples R China; [Gao, Zhengnan] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Shanghai, Peoples R China; [Su, Qing] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China; [Mu, Yiming] Shandong Univ, Shandong Prov Hosp, Jinan, Peoples R China; [Zhao, Jiajun; Chen, Lulu; Zeng, Tianshu] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China; [Yu, Xuefeng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China; [Li, Qiang] Harbin Med Univ, Affiliated Hosp 2, Harbin, Peoples R China; [Shen, Feixia] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China; [Chen, Li] Shandong Univ, Qilu Hosp, Jinan, Peoples R China; [Zhang, Yinfei] Cent Hosp Shanghai Fading Dist, Shanghai, Peoples R China; [Wang, Youmin] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China; [Deng, Huacong] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China; [Liu, Chao] Jiangsu Prov Hosp Integrat Chinese & Western Med, Nanjing, Peoples R China; [Wu, Shengli] Karamay Municipal Peoples Hosp, Karamay, Xinjiang, Peoples R China; [Yang, Tao] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China; [Li, Mian; Xu, Yu; Xu, Min; Wang, Tiange; Zhao, Zhiyun; Lu, Jieli; Bi, Yufang; Wang, Weiqing; Ning, Guang] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Endocrine & Metab Dis,Shanghai Inst Endocrin, Shanghai, Peoples R China; [Li, Mian; Xu, Yu; Xu, Min; Wang, Tiange; Zhao, Zhiyun; Lu, Jieli; Bi, Yufang; Wang, Weiqing; Ning, Guang] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp,Shanghai Natl Clin Res Ctr Metab Dis, Shanghai Natl Ctr Translat Med,Key Lab Endocrine, Shanghai, Peoples R China"

通信作者："Chen, G (通讯作者)，Fujian Med Univ, Shengli Clin Med Coll, Fujian Prov Hosp, Dept Endocrinol, Fuzhou, Peoples R China."

来源：EUROPEAN JOURNAL OF NUTRITION

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000740638700003

JCR分区：Q1

影响因子：5

年份：2022

卷号：61

期号：3

开始页：1609

结束页：1620

文献类型：Article

关键词：Soy; Cardiovascular disease; Myocardial infarction; Cerebral infarction; Heart failure; All-cause mortality

摘要："Purpose This study aimed to clarify the association of soy intake with cardiovascular disease (CVD) and all-cause mortality. Methods We conducted a prospective cohort study in a Chinese population composed of 97,930 participants aged >= 40 years old without CVD at baseline in 2011. Habitual soy intake over a period of 12 months was evaluated using a food frequency questionnaire. All participants were classified into four groups based on their soy food consumption levels: < 15, 15-29, 30-59, and >= 60 g/day, with the lowest category as the reference group. Follow-up was conducted between 2014 and 2016 to assess CVD incidence and all-cause mortality since baseline, which was collected from the local mortality and disease registers of the National Disease Surveillance Point System and National Health Insurance System. The Cox proportional hazards regression models were used to analyze the relationship of soy intake with later CVD events and all-cause mortality. Results During 350,604 person-years of follow-up (median [interquartile range]: 3.16 [2.98, 4.77] years), 2523 total CVD events and 1473 all-cause mortalities were documented. After controlling for covariates, the hazard ratios (95% confidence intervals) for total CVD events across increasing soy intake levels were 1.03 (0.93-1.14); 0.96 (0.86-1.07); and 0.86 (0.75-0.98; p for trend = 0.0434), while those for all-cause mortality were 0.88 (0.77-1.02); 0.86 (0.74-1.00); and 0.83 (0.69-0.99; p for trend = 0.0084). Conclusion High soy intake was associated with a reduced risk of total CVD events and all-cause mortality among a Chinese population."

基金机构："Ministry of Science and Technology of the People's Republic of China [2016YFC0901203, 2016YFC1305600, 2016YFC1305202, 2016YFC1304904, 2017YFC1310700, 2018YFC1311705, 2018YFC1311800]; Chinese Medical Association Foundation [12020240314]; Chinese Endocrine Society [12020240314]; Chinese Academy of Medical Sciences [2018PT32017, 2019PT330006]; Shanghai Medical and Health Development Foundation [DMRFP_I_01]; Clinical Research Plan of SHDC [SHDC2020CR3064B]; Science and Technology Committee of Shanghai [19411964200, 20Y11905100]; National Key New Drug Creation and Manufacturing Program of the Ministry of Science and Technology [2012ZX09303006-001]; Startup Fund for Scientific Research of Fujian Medical University [2017XQ1138]"

基金资助正文："This research was funded by the Ministry of Science and Technology of the People's Republic of China (Grant Numbers: 2016YFC0901203, 2016YFC1305600, 2016YFC1305202, 2016YFC1304904, 2017YFC1310700, 2018YFC1311705, and 2018YFC1311800), the Chinese Medical Association Foundation and Chinese Endocrine Society (Grant Number: 12020240314), Chinese Academy of Medical Sciences (Grant No. 2018PT32017, 2019PT330006) Shanghai Medical and Health Development Foundation (Grant No. DMRFP_I_01), Clinical Research Plan of SHDC (Grant No. SHDC2020CR3064B), and Science and Technology Committee of Shanghai (Grant No. 19411964200 and 20Y11905100), the National Key New Drug Creation and Manufacturing Program of the Ministry of Science and Technology (Grant Number: 2012ZX09303006-001), and Startup Fund for Scientific Research of Fujian Medical University (Grant No. 2017XQ1138)."